Otter Creek Advisors LLC Invests $2.37 Million in Danaher Corporation $DHR

Key Points

• Otter Creek Advisors LLC invested approximately $2.37 million in Danaher Corporation, acquiring 12,000 shares in the second quarter.
• Several large investors have increased their holdings in Danaher, with MGO One Seven LLC leading with an impressive 485.7% growth.
• Analysts have set optimistic price targets for Danaher, ranging from $220.00 to $275.00, reflecting a strong consensus rating of "Moderate Buy" based on 17 "Buy" and 6 "Hold" ratings.

Otter Creek Advisors LLC bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,000 shares of the conglomerate's stock, valued at approximately $2,370,000.

Other large investors have also modified their holdings of the company. MGO One Seven LLC grew its holdings in shares of Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after buying an additional 20,813 shares in the last quarter. Chicago Capital LLC grew its holdings in shares of Danaher by 11.6% during the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate's stock worth $2,634,000 after buying an additional 1,391 shares in the last quarter. UniSuper Management Pty Ltd grew its holdings in shares of Danaher by 1.6% during the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock worth $34,954,000 after buying an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in shares of Danaher during the first quarter worth $539,000. Finally, Horizon Financial Services LLC grew its holdings in shares of Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after buying an additional 8,160 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Robert W. Baird upped their price objective on shares of Danaher from $229.00 to $236.00 and gave the company an "outperform" rating in a report on Wednesday. Redburn Partners set a $220.00 price objective on shares of Danaher in a report on Wednesday, October 8th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Evercore ISI upped their price objective on shares of Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a report on Tuesday, October 7th. Finally, Barclays reissued an "overweight" rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $245.00.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company's stock.

Danaher Trading Down 0.8%

Shares of DHR stock opened at $209.14 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm has a market cap of $149.76 billion, a PE ratio of 44.50, a price-to-earnings-growth ratio of 3.01 and a beta of 0.77. The company has a 50-day moving average of $201.60 and a two-hundred day moving average of $197.29. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $275.51.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.